Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Colorcon
Moodys
AstraZeneca
McKesson

Last Updated: November 27, 2022

CLINICAL TRIALS PROFILE FOR ABALOPARATIDE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Abaloparatide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01343004 ↗ Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women Completed Radius Health, Inc. Phase 3 2011-04-01 The purpose of this study is to determine whether BA058 (abaloparatide), a parathyroid hormone-related peptide, is effective in preventing fractures in postmenopausal women with severe osteoporosis who are at risk of fractures.
NCT01657162 ↗ Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis Completed Radius Health, Inc. Phase 3 2012-11-20 The purpose of this study is to provide 24 months of standard of care data on participants previously enrolled in Study BA058-05-003 (NCT02653417).
NCT01674621 ↗ Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis Completed Nordic Bioscience A/S Phase 2 2012-09-25 To determine the clinical safety and efficacy of abaloparatide transdermal in otherwise healthy postmenopausal women with osteoporosis as assessed by changes in bone mineral density (BMD) and serum markers of bone metabolism when compared to transdermal placebo and abaloparatide injection for 6 months of treatment.
NCT01674621 ↗ Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis Completed Radius Health, Inc. Phase 2 2012-09-25 To determine the clinical safety and efficacy of abaloparatide transdermal in otherwise healthy postmenopausal women with osteoporosis as assessed by changes in bone mineral density (BMD) and serum markers of bone metabolism when compared to transdermal placebo and abaloparatide injection for 6 months of treatment.
NCT03512262 ↗ Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM) Completed Radius Health, Inc. Phase 3 2018-03-30 A 12 month study to measure the efficacy and safety of abaloparatide in men with osteoporosis.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Abaloparatide

Condition Name

Condition Name for Abaloparatide
Intervention Trials
Osteoporosis 5
Osteoporosis, Postmenopausal 3
Postmenopausal Osteoporosis 2
Osteoporosis Localized to Spine 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Abaloparatide
Intervention Trials
Osteoporosis 8
Osteoporosis, Postmenopausal 6
Fractures, Bone 3
Hip Fractures 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Abaloparatide

Trials by Country

Trials by Country for Abaloparatide
Location Trials
United States 40
Poland 7
Italy 3
Estonia 3
Denmark 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Abaloparatide
Location Trials
Georgia 5
Colorado 5
New York 4
Maryland 4
Pennsylvania 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Abaloparatide

Clinical Trial Phase

Clinical Trial Phase for Abaloparatide
Clinical Trial Phase Trials
Phase 4 4
Phase 3 4
Phase 2 5
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Abaloparatide
Clinical Trial Phase Trials
Recruiting 6
Completed 5
Not yet recruiting 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Abaloparatide

Sponsor Name

Sponsor Name for Abaloparatide
Sponsor Trials
Radius Health, Inc. 8
Hospital for Special Surgery, New York 2
Johns Hopkins University 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Abaloparatide
Sponsor Trials
Other 17
Industry 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Express Scripts
McKesson
Moodys
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.